The Recombigen HIV-1 Latex Agglutination (LA) Test was recently licensed by the U.S. Food and Drug Administration for use as a rapid screening assay for human immunodeficiency virus type 1 (HIV-1) antibodies. However, its performance in various settings and in different populations has not been firmly established. Consequently, we evaluated the test in the Cleveland Clinic Retrovirus Laboratory, a regional reference laboratory for HIV diagnostic testing and a testing laboratory for the Ohio Department of Health Anonymous HIV Testing and Counseling Program. Serum samples from 93 individuals presumed to be at high risk for HIV infection were evaluated. The sera were initially tested for HIV antibodies by enzyme-linked immunosorbent assay (ELISA). All repeatedly reactive sera were subjected to confirmatory Western blot (WB; immunoblot) testing. Of 97 serum specimens tested (5 were from one seroconverter), 44 were repeatedly reactive by ELISA and 53 were nonreactive. Of the reactive serum specimens, 31 were confirmed positive and 12 were indeterminate by WB. All of the sera were coded and then retested by the LA test. Of 53 serum specimens nonreactive by ELISA, 51 were also nonreactive in the LA test. Of the 44 serum specimens reactive by ELISA, 16 were nonreactive by LA; however, 3 of the latter were WB positive. No serum specimen with an ELISA ratio (specimen optical density/cutoff optical density) of less than 2.1 scored reactive in the LA test. The LA test was positive for only two of five consecutive serum specimens from a seroconverter despite the fact that all but the earliest of these were ELISA reactive and WB positive. Although the LA test appears to be an adequate first-line screening test when appropriately used according to the directions of the manufacturer, our data suggest that occasional sera with low levels of reactivity by ELISA may not be readily detected as reactive by the LA test.
Enzyme-linked immunosorbent assays (ELISA) are currently the standard mode of screening for antibodies to human immunodeficiency virus type 1 (HIV-1) (1, 4; T. C. Quinn, Letter, J. Am. Med. Assoc. 261:1148, 1989). They are highly sensitive and specific assays and have been extensively used in blood banks, in acquired immune deficiency syndrome testing and counseling programs, and as tests for diagnosis of HIV infection. In less developed countries, however, facilities, environmental conditions, and economics have not permitted the wide application of ELISA-based tests, despite the fact that large numbers of persons in these countries are at high risk of infection (4, 5) .
In December 1988, the U.S. Food and Drug Administration (FDA) licensed a new HIV antibody screening assay, the principle of which is based on latex agglutination. The Recombigen HIV-1 Latex Agglutination (LA) Test (Cambridge Bioscience, Worcester, Mass.) requires a minimum of equipment, can be performed in as little as 5 min, and is ideally suited for use in settings where sophisticated laboratory equipment is not available (6, 7) .
Although the LA test has been evaluated in a limited number of trials (2, 6, 9, 11) Fresh sera stored at 2 to 8°C for less than 1 week and sera stored frozen (-20°C) for less than 6 months were selected for testing. Specimens were from sexually transmitted disease clinics, drug treatment clinics, or patients referred to infectious disease physicians for evaluation of possible HIV infection. Clinical diagnoses were not available to the laboratory, but all sera were presumed to be from individuals at risk of infection with HIV. Selection of sera was based on initial ELISA screening for antibodies to HIV-1. Among the sera of 93 individuals tested were 5 consecutive serum specimens from a documented HIV seroconverter, 14 serum specimens reactive for hepatitis B virus core antibody but nonreactive for HIV, and 1 serum specimen reactive for the antibody to human T-lymphotropic virus type I/II. Heparinized whole blood of 12 patients from whom HIV had been isolated in culture was tested in addition to the sera described.
All sera were first tested for antibodies to HIV-1 by lymphadenopathy virus (LAV) ELISA (Genetic Systems, Seattle, Wash.). Initially reactive specimens were retested in duplicate to verify reactivity. A P/C ratio (patient specimen optical density/cutoff optical density) was determined for each specimen, and an average P/C ratio based on the three ratios was calculated for each reactive specimen (range, 1.2 to 10.2). Nonreactive specimens had initial P/C ratios of less than 1.0. Repeatedly reactive specimens were (3) . By the criteria of the conference, a positive WB requires the presence of at least two of the following three bands: p24, gp4l, and gp120/160; blots bearing any other band(s) are deemed indeterminate.
The Recombigen LA test kit contains a colloidal suspension of latex beads coated with purified recombinant gp4l and gpl20 envelope polypeptides (7, 10 RI) of the prediluted negative serum and 1 drop the positive control serum were placed on separate circles and spread over the area enclosed by the circles with a transfer loop (contained in the kit). A drop of sample diluent was then added to each of the four remaining circles, and separate transfer loops were used to pick up and deliver each patient specimen to the card, yielding a final specimen dilution of 1:10. With the transfer loop, the specimen was mixed with the diluent and spread over the entire surface of the circle. One drop (approximately 15 ,ul) of latex bead suspension was next added to each sample and control circle, and the cards were rotated on an orbital rotator at 30 to 60 rpm for 3 min at room temperature. A cover was placed over the card during rotation to prevent drying the reagents. The agglutination patterns were read immediately (within 30 to 60 s) with the assistance of a high-intensity lamp and a magnifier. Positive specimens yielded agglutination reactions ranging from 1+ to 4+, whereas positive control agglutinations ranged from 1+ to 3+ (scale, 0 to 4+). A 1+ reaction was characterized by very fine aggregates against a milky-white background, and a 4+ pattern had larger clumps of beads with no milky-white background. Negative reactions were milky-white and exhibited no visible agglutination when compared with the negative control. Because we found it difficult to interpret a 1 + reaction (even as demonstrated by the interpretation panel) and often had to scrutinize the cards closely, gloves, a mask, and protective eyewear were worn by the technologist.
Ninety-seven serum specimens (from 93 individuals) were tested, and the results are summarized in Fig. 1 . Among the 44 ELISA-reactive serum specimens, 70% were confirmed positive by WB, 27% were indeterminate (5 specimens had only a pl7 band, 6 had only a p24 band, and 1 had both a pl7 and a p24 band), and 2% were negative. For antibodies to the hepatitis B virus core antigen nor a single serum sample having ELISA reactivity for human T-lymphotropic virus type I/II had reactivity for HIV-1 by LA or ELISA, although data from the manufacturer (LA test kit brochure) and other sources (6, 11) suggest that one might expect some false LA reactivity with sera from patients with conditions unrelated to HIV infection.
Compared with ELISA, the sensitivity of the LA test was 63.6% and the specificity was 96.2%. However, when compared with sera confirmed reactive by WB, the sensitivity of the LA test was 90.3%. We were unable to calculate specificity in the latter case because we do not routinely do WB on sera that are ELISA nonreactive. When the two discrepant sera that were LA reactive (but ELISA nonreactive) were subsequently subjected to WB analysis, one was negative and the other was indeterminate (with an apparently nonspecific band at 70 kilodaltons). Why these would weakly agglutinate in the LA test is unknown; however, they were variously scored as both reactive and nonreactive in several repeat tests done by the same technologist. The 16 serum specimens that were ELISA reactive but LA nonreactive all had ELISA P/C ratios ranging from 1.2 to 2.9. Of particular significance is the fact that 3 of these 16 serum specimens were WB reactive. One of these serum specimens was from a sexually transmitted disease clinic patient whose ELISA P/C ratio was 2.9, with WB bands at p24, gp4l, p5l, p66, and gpl20/160. The other two were nonconsecutive serum specimens from a documented seroconverter ( Because there appeared to be an ELISA P/C ratio below which reactivity in the LA test was difficult to discern, we calculated the ELISA P/C ratios of the individual samples constituting the LA interpretation panel provided by the manufacturer. The 4+, 3+, 2+, and 1+ samples had ratios of 8.5, 7.4, 6.6, and 5.7, respectively, whereas the LAnegative sample was ELISA nonreactive. Thus, the interpretation panel sample with the lowest LA reactivity had an ELISA P/C ratio well above the ratios of those sera that we were unable to classify as reactive in the LA test, further suggesting that some specimens minimally reactive by ELISA will be scored as nonreactive in the LA test. The sensitivity of the Recombigen LA test as stated by the manufacturer is 99.4%, based on 100% prevalence of HIV-1 antibody in clinically diagnosed acquired immune deficiency syndrome patients. The specificity of the test is 99.5%, based on 0% prevalence of HIV-1 antibody in blood donors in the United States. This differs from the sensitivity and specificity observed in our study; however, our calculations were based on a comparison of LA with ELISA that used sera from individuals presumed to be at high risk for HIV infection rather than from patients with a clinical diagnosis of acquired immune deficiency syndrome or from blood donors. In preclinical studies, specificity in a doctor's office and two hospital emergency rooms ranged from 88.7 to 98.0% (LA test kit brochure). Data from the doctor's office revealed an LA-reactive rate of 10.9% compared with an ELISA-reactive rate of 0%. In one emergency room, the LA-reactive rate was 15.1% versus an ELISA-reactive rate of only 1.9%. These and more recent findings of differences in sensitivity and specificity between the LA test and ELISA (4, 9, 11) 28, 1990 
